Abstract:BackgroundTumor microenvironment (TME) status is closely related to breast cancer (BC) prognosis and systemic therapeutic effects. However, to date studies have not considered the interactions of immune and stromal cells at the gene expression level in BC as a whole. Herein, we constructed a predictive model, for adjuvant decision-making, by mining TME molecular expression information related to BC patient prognosis and drug treatment sensitivity.MethodsClinical information and gene expression profiles were extracted from The Cancer Genome Atlas (TCGA), with patients divided into high- and low-score groups according to immune/stromal scores. TME-related prognostic genes were identified using Kaplan-Meier analysis, functional enrichment analysis, and protein-protein interaction (PPI) networks, and validated in the Gene Expression Omnibus (GEO) database. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis was used to construct and verify a prognostic model based on TME-related genes. In addition, the patients’ response to chemotherapy and immunotherapy was assessed by survival outcome and immunohistochemistry (IPS). Immunohistochemistry (IHC) staining laid a solid foundation for exploring the value of novel therapeutic target genes.ResultsBy dividing patients into low- and high-risk groups, a significant distinction in overall survival was found (p < 0.05). The risk model was independent of multiple clinicopathological parameters and accurately predicted prognosis in BC patients (p < 0.05). The nomogram-integrated risk score had high prediction accuracy and applicability, when compared with simple clinicopathological features. As predicted by the risk model, regardless of the chemotherapy regimen, the survival advantage of the low-risk group was evident in those patients receiving chemotherapy (p < 0.05). However, in patients receiving anthracycline (A) therapy, outcomes were not significantly different when compared with those receiving no-A therapy (p = 0.24), suggesting these patients may omit from A-containing adjuvant chemotherapy. Our risk model also effectively predicted tumor mutation burden (TMB) and immunotherapy efficacy in BC patients (p < 0.05).ConclusionThe prognostic score model based on TME-related genes effectively predicted prognosis and chemotherapy effects in BC patients. The model provides a theoretical basis for novel driver-gene discover in BC and guides the decision-making for the adjuvant treatment of early breast cancer (eBC).

Prognostic and Predictive Value of a Metabolic Risk Score Model in Breast Cancer: an Immunogenomic Landscape Analysis

A Systematic Analysis of a Potential Metabolism-Related Prognostic Signature for Breast Cancer Patients

A Metabolic Gene Signature to Predict Breast Cancer Prognosis

Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

A Metabolism-Related Gene Signature Predicts the Prognosis of Breast Cancer Patients: Combined Analysis of High-Throughput Sequencing and Gene Chip Data Sets

Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Prognosis and stratification of breast cancer immune infiltration status based on a mitochondria-related gene signature.

The Immunological Contribution of a Novel Metabolism-Related Signature to the Prognosis and Anti-Tumor Immunity in Cervical Cancer.

Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients

Metabolism-related gene vaccines and immune infiltration in ovarian cancer: A novel risk score model of machine learning

Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature

Computational dissection of the regulatory mechanisms of aberrant metabolism in remodeling the microenvironment of breast cancer

A Prognostic Mathematical Model Based on Tumor Microenvironment-Related Genes Expression for Breast Cancer Patients

Tumor Microenvironment-Related Multigene Prognostic Prediction Model for Breast Cancer

Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature

Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma

A Novel Metabolic Gene Signature-Based Nomogram to Predict Overall Survival in Breast Cancer

Prognosis stratification and response to treatment in breast cancer based on one-carbon metabolism-related signature

In Silico analysis and linking of metabolism-related genes with the immune landscape in head and neck squamous cell carcinoma